Correlation Between Vertex Pharmaceuticals and Viridian Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Vertex Pharmaceuticals and Viridian Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vertex Pharmaceuticals and Viridian Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vertex Pharmaceuticals and Viridian Therapeutics, you can compare the effects of market volatilities on Vertex Pharmaceuticals and Viridian Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vertex Pharmaceuticals with a short position of Viridian Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vertex Pharmaceuticals and Viridian Therapeutics.

Diversification Opportunities for Vertex Pharmaceuticals and Viridian Therapeutics

0.6
  Correlation Coefficient

Poor diversification

The 3 months correlation between Vertex and Viridian is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Vertex Pharmaceuticals and Viridian Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viridian Therapeutics and Vertex Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vertex Pharmaceuticals are associated (or correlated) with Viridian Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viridian Therapeutics has no effect on the direction of Vertex Pharmaceuticals i.e., Vertex Pharmaceuticals and Viridian Therapeutics go up and down completely randomly.

Pair Corralation between Vertex Pharmaceuticals and Viridian Therapeutics

Given the investment horizon of 90 days Vertex Pharmaceuticals is expected to under-perform the Viridian Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Vertex Pharmaceuticals is 1.91 times less risky than Viridian Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Viridian Therapeutics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  2,112  in Viridian Therapeutics on September 21, 2024 and sell it today you would lose (273.00) from holding Viridian Therapeutics or give up 12.93% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Vertex Pharmaceuticals  vs.  Viridian Therapeutics

 Performance 
       Timeline  
Vertex Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Vertex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Viridian Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Vertex Pharmaceuticals and Viridian Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Vertex Pharmaceuticals and Viridian Therapeutics

The main advantage of trading using opposite Vertex Pharmaceuticals and Viridian Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vertex Pharmaceuticals position performs unexpectedly, Viridian Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will offset losses from the drop in Viridian Therapeutics' long position.
The idea behind Vertex Pharmaceuticals and Viridian Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities